- Home
- POAS vs HURA Comparison
POAS vs HURA Comparison
Compare POAS & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POAS
- HURA
- Stock Information
- Founded
- POAS 2017
- HURA 2009
- Country
- POAS Singapore
- HURA United States
- Employees
- POAS N/A
- HURA N/A
- Industry
- POAS Industrial Machinery/Components
- HURA
- Sector
- POAS Industrials
- HURA
- Exchange
- POAS Nasdaq
- HURA Nasdaq
- Market Cap
- POAS 114.0M
- HURA 131.8M
- IPO Year
- POAS 2025
- HURA N/A
- Fundamental
- Price
- POAS $3.88
- HURA $1.98
- Analyst Decision
- POAS
- HURA Strong Buy
- Analyst Count
- POAS 0
- HURA 2
- Target Price
- POAS N/A
- HURA $11.50
- AVG Volume (30 Days)
- POAS 1.3M
- HURA 182.6K
- Earning Date
- POAS 01-01-0001
- HURA 11-14-2025
- Dividend Yield
- POAS N/A
- HURA N/A
- EPS Growth
- POAS N/A
- HURA N/A
- EPS
- POAS N/A
- HURA N/A
- Revenue
- POAS $128,328.00
- HURA N/A
- Revenue This Year
- POAS N/A
- HURA N/A
- Revenue Next Year
- POAS N/A
- HURA N/A
- P/E Ratio
- POAS N/A
- HURA N/A
- Revenue Growth
- POAS N/A
- HURA N/A
- 52 Week Low
- POAS $3.70
- HURA $1.80
- 52 Week High
- POAS $4.30
- HURA $7.20
- Technical
- Relative Strength Index (RSI)
- POAS N/A
- HURA 28.73
- Support Level
- POAS N/A
- HURA $2.01
- Resistance Level
- POAS N/A
- HURA $2.60
- Average True Range (ATR)
- POAS 0.00
- HURA 0.15
- MACD
- POAS 0.00
- HURA -0.05
- Stochastic Oscillator
- POAS 0.00
- HURA 1.47
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.